Shanghai Henlius Biotech Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China
Reuters
Sep 30
<a href="https://laohu8.com/S/SGBCF">Shanghai Henlius Biotech</a> Receives Regulatory Approval to Begin Phase 1b/2 Clinical Trial of HLX43 Combination Therapy for Advanced Solid Tumours in China
**Shanghai Henlius Biotech Receives Regulatory Approval for New Cancer Clinical Trial** Shanghai Henlius Biotech Inc. announced that its application to conduct a Phase 1b/2 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) in combination with HLX07 (a recombinant anti-EGFR humanised monoclonal antibody injection) has been approved by China's National Medical Products Administration. The trial will focus on the treatment of advanced or metastatic solid tumours. Recent results from the phase 1 clinical trial, presented at the 2025 World Conference on Lung Cancer, showed promising efficacy and safety in patients with advanced solid tumours, particularly non-small cell lung cancer. The approval is specific to Shanghai Henlius Biotech Inc., with no indication of grant or funding involvement from other organizations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.